Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2024		Dec. 31, 2023
Assets
Investments, at fair value		$ 14,220.8	[1]	$ 14,649.0
Cash		234.0		223.0
Foreign currency, at fair value (cost—$8 and $8, respectively)		8.0		8.0
Receivable for investments sold and repaid		329.0		246.0
Income receivable		300.0		290.0
Unrealized appreciation on foreign currency forward contracts		19.0		13.0
Deferred financing costs		31.0		32.0
Prepaid expenses and other assets		10.0		8.0
Total assets		15,152.0		15,469.0
Liabilities
Payable for investments purchased		0.0		0.0
Debt (net of deferred financing costs and discount of $34 and $36, respectively)	[2]	7,934.0		8,187.0
Unrealized depreciation on foreign currency forward contracts		2.0		4.0
Stockholder distributions payable		196.0		196.0
Management fees payable		55.0		56.0
Subordinated income incentive fees payable	[3]	43.0		41.0
Administrative services expense payable		6.0		5.0
Interest payable		91.0		98.0
Other accrued expenses and liabilities		13.0		33.0
Total liabilities		8,340.0		8,620.0
Commitments and contingencies	[4]
Stockholders’ equity
Preferred stock, $0.001 par value, 50,000,000 shares authorized, none issued and outstanding		0.0		0.0
Common stock, $0.001 par value, 750,000,000 shares authorized, 280,066,433 and 280,066,433 shares issued and outstanding, respectively		0.0		0.0
Capital in excess of par value		9,437.0		9,437.0
Retained earnings (accumulated deficit)	[5]	(2,625.0)		(2,588.0)
Total stockholders’ equity		6,812.0		6,849.0
Total liabilities and stockholders’ equity		$ 15,152.0		$ 15,469.0
Net asset value per share of common stock at period end (in dollars per share)		$ 24.32		$ 24.46
Non-controlled/unaffiliated
Assets
Investments, at fair value		$ 9,763.0		$ 10,568.0
Non-controlled/affiliated
Assets
Investments, at fair value		751.5		745.4
Controlled/affiliated
Assets
Investments, at fair value		$ 3,706.2		$ 3,335.7

[1] See Note 8 for additional information regarding the fair value of the Company’s financial instruments

[2] See Note 9 for a discussion of the Company’s financing arrangements.

[3] See Note 2 and 4 for a discussion of the methodology employed by the Company in calculating the subordinated income incentive fees.

[4] See Note 10 for a discussion of the Company’s commitments and contingencies.

[5] See Note 5 for a discussion of the sources of distributions paid by the Company.